Oxford BioTherapeutics entered an expanded deal with WuXi Biologics potentially worth more than $450 million to develop five bispecific antibodies for the treatment of several cancer types using the latter's WuXiBody platform, the companies announced Tuesday. Under the agreed terms, WuXi Biologics will receive an undisclosed upfront payment as well as development, regulatory and commercial milestones, in addition to royalties based on global sales.
Christian Rohlff, CEO of Oxford BioTherapeutics, noted that combining the company's immune-oncology medicines "with a major check-point pathway into a single entity, with potential broad utility across many solid and liquid tumour types, is designed to generate novel therapies for patients who do not benefit from the existing…medicines."
The companies explained that the WuXiBody platform can break through barriers of bispecific antibodies development and speed up the process by six to 18 months while reducing manufacturing costs. The firms added that the platform "enables almost any mAb sequence pairs to be assembled into bispecific constructs", which are characterised as having low immunogenicity, a similarly long half-life in vivo as monoclonal antibodies and excellent stability.
WuXi Biologics CEO Chris Chen said "this is the third partnership we signed since we globally launched this exciting platform this September." In September, I-Mab Biopharma expanded its partnership with WuXi Biologics and licenced the WuXiBody platform to develop three bispecific antibodies. Meanwhile, WuXi Biologics inked a deal last month with ABL Bio seeking to develop multiple bispecific antibodies based on the platform. Most recently, WuXi Biologics announced a strategic collaboration with Brii Biosciences aiming to expedite the development of the latter's pipeline, providing Brii Bio access to WuXi Biologics' entire antibody platform capabilities including the WuXiBody technology to discover novel bispecific antibodies.
To read more Top Story articles, click here.